CML: Nilotinib Yields High One-Year Survival in Accelerated-Phase Patients Resistant to Imatinibdoi:10.1097/01.COT.0000303250.86685.5eFuerst, MarkOncology Times
Effect of Time to Major Molecular Response on Survival: Testing in Community Practice Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML), allowing prolonged remissions in patients with chronic-phase disease. However,... Radich,P Jerald - 《Clinical Leukemia》 被引量: 33发表...
该研究正式发表于2014年9月28日 《白血病》 杂志上(Leukemia. 2014 Oct;28(10):1988-92)。 Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in c...
CML治疗解析 慢性髓性白血病CML 福建医科大学附属协和医院血液科 沈建箴 慢性髓性白血病－CML 又称为：慢性粒细胞白血病，是白血病的一种，属于恶性肿瘤病因与体内出现染色体突变有关－－出现费城（Ph＋）染色体特征:是骨髓中髄细胞恶变产生大量异常粒细胞的一种疾病－－白细胞升高 CML的细胞遗传学异常...
[6] Additionally, a follow-up study showed significant improvement in 8-year event survival, freedom from progression to accelerated phase or blast phase, and overall survival. [7] Several studies have evaluated the efficacy and safety of higher doses of imatinib (800 mg) in newly diagnosed ...
ChronicPhaseCMLSurvivalbyTherapyType 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Year1Year4Year7Year10Year13Year16Year19 P e r c e n t o f P a t i e n t s A l i v e BMT IFN GLIVEC OTHER allCML expected 8
ABSTRACT: Imatinib mesylate has had a significant impact on the survival of patients with chronic myeloid leukemia (CML), particularly chronic-phase (CP) disease. However, a proportion of patients lose their response, fail to respond, or are intolerant to imatinib. The second-generation tyrosine ...
especially again in the first year. We’ve learned that there’s no statistically significant difference in survival, but if you look at CML-related deaths, there was clearly a decrease in the number of CML-related deaths that was not offset completely by other non-CML-related deaths, includi...
--- Part Of CMLHope.Com An International Community Of CML Patients For more information:http://cmlhope.com Post Message: cml@yahoogroups.com Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change...
Survival advantage with imatinib compared with combination interferon–α in chronic phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108: 1478–1484. Article CAS Google Scholar Marin D, Ibrahim AR, Goldman JM . European Treatment and Outcome Study (...